Pharmacokinetic interaction between rifampicin and ritonavir‐boosted atazanavir in HIV‐infected patients*
- 7 March 2007
- journal article
- Published by Wiley in HIV Medicine
- Vol. 8 (2) , 131-134
Abstract
Tuberculosis (TB) is a common opportunistic infection among HIV-infected people, and rifampicin is an important drug for the treatment of TB. However, administration of rifampicin in combination with antiretroviral therapy, particularly protease inhibitors, is difficult because of drug-drug interactions. We have performed a prospective study in three HIV-infected patients with TB treated with a rifampicin-containing regimen (rifampicin 600 mg per day) and antiretroviral therapy including only nucleoside reverse transcriptase inhibitors (NRTIs) plus atazanavir 300 mg once a day (qd) and ritonavir 100 mg qd, to evaluate whether the inducing effect of rifampicin on the drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 could be overcome by the inhibitory effect of ritonavir. A complete pharmacokinetic evaluation of the steady-state concentrations of atazanavir and ritonavir was performed. In all three cases, more than 50% of the time the atazanavir level was below the minimum recommended trough plasma level (150 ng/mL according to current pharmacokinetic guidelines) to inhibit HIV wild-type replication. These results strongly indicate that the administration of rifampicin with a combination of atazanavir 300 mg qd plus ritonavir 100 mg qd must be avoided because subtherapeutic concentrations of atazanavir are produced.Keywords
This publication has 17 references indexed in Scilit:
- Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2006
- Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2004
- AtazanavirDrugs, 2003
- Rifampin and Rifabutin Drug InteractionsArchives of internal medicine (1960), 2002
- Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with TuberculosisClinical Pharmacokinetics, 2002
- AIDS across Europe, 1994–98: the EuroSIDA studyThe Lancet, 2000
- Ritonavir Enables Combined Therapy with Rifampin and SaquinavirClinical Infectious Diseases, 1999
- The role of intestinal P-glycoprotein in the interaction of digoxin and rifampinJournal of Clinical Investigation, 1999
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.Journal of Clinical Investigation, 1992